

Guerbet and Intrasense announce the CE marking of DUOnco™ Liver, an artificial intelligence algorithm designed to detect focal liver lesions

Montpellier, France, 23rd September 2024 at 5:45 CEST

Guerbet (FR0000032526 GBT), worldwide leader in medical imaging, and Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announce the CE marking under MDR of the liver AI developed by Guerbet (trading name: DUOnco™ Liver).

Detecting and monitoring liver cancer: a major challenge

Liver cancer remains a major challenge of great importance for public health. In 2022, liver cancer was classified as the 6th most common cancer in the world, with over 866,000 new cases diagnosed, and the third cause of cancer death, with a death toll of over 758,000¹. The hepatic metastases are also the most common cancerous hepatic tumors².

Despite the technological advances in medical imaging, the detecting and follow-up of liver cancer, whether primary or secondary (metastases), remain a challenge, particularly when analysing CT scanner images. The interpretation of liver scan is complex, with a risk of missing certain lesions and a process for measuring all focal lesions in the liver manually, time-consuming and tedious. A study by the University Hospital of Kyoto² shows the difficulty of detecting metastases in routine clinical practice, since 50% of them had not been identified in current practice. Finally, the constant raise in number of patients creates an exponential growth of data to analyse, making radiologist face more and more challenges in terms of work volume, diagnosis complexity, and oncology follow-up.

A cutting-edge AI at the service of liver oncology

In response to these oncology imaging challenges, Guerbet launched a new brand of artificial intelligence solutions: DUOnco™, whose algorithms will be integrated into Intrasense solutions but will also be sold individually.

The French group then developed DUOnco™ Liver, cutting-edge artificial intelligence algorithm developed specifically to detect focal lesions in the liver during portal phase

¹ Studies: https://gco.iarc.fr/today/home_11-liver-and-intrahepatic-bile-ducts-fact-sheet.pdf (who.int)

² "Artificial intelligence-powered software detected more than half of the liver metastases overlooked by radiologists on contrast-enhanced CT", Nakai, Hirotsugu et al. European Journal of Radiology, Volume 163.

scans. DUOnco™ Liver automatically detects, segments and measures the focal lesions in the liver, whilst being more precise and saving significant time, all are essential elements to optimize care for patients.

“Obtaining certification for our DUOnco™ Liver AI represents a significant step forward in our innovation strategy. We developed this algorithm with the conviction that it could be a real game-changer in helping to detect and monitor liver metastases” says **François Nicolas, Head of Research, Development, Innovation and AI at Guerbet.**

Integrating multiorgan AIs to Liflow® 2.0

The 2.0 version of Liflow®, enriched by the integration of DUOnco™ Liver, reflects Intrasense’s commitment to provide high-tech medical imaging solutions, meeting the highest expectations of radiologists. Already installed on the first test sites, Liflow® continues to be developed and enriched with new AI algorithms.

This synergy between Intrasense’s expertise and Guerbet’s innovation guaranty a powerful tool to help healthcare professionals to diagnose and monitor liver cancer. Liflow® 2.0, enriched with multiorgan AI algorithms embodies a new era for clinical approach to oncology follow-up, combining efficiency, precision and ergonomics.

Alexandre Salvador, CEO at Intrasense continues: “We are extremely proud to see the liver algorithm, developed by Guerbet, receive the CE marking and be enriched to our solution Liflow® 2.0. This recognition validates not only the technological excellence of our solution, but also our commitment to offer healthcare professionals high quality tools. In five months, it is the second Guerbet AI we transfer, witnessing a great synergy in our technical collaboration. It is a decisive step in our mission to help making more precise, faster, and more accessible diagnosis.”

About Guerbet

At Guerbet, we build lasting relationships to help people live better. This is our raison d'être. We are a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices and digital and AI solutions for diagnostic and interventional imaging. A pioneer for 95 years in the field of contrast media, with more than 2,830 employees worldwide, we are constantly

innovating and devote 10% of our sales to Research & Development in four centers in France, Israel and the United States. Guerbet (GBT) is listed in compartment B of Euronext Paris and achieved a turnover of €786 million in 2023.

For further information, please visit www.guerbet.com.

About Intrasense

A French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries, facilitating and securing diagnosis, decision-making and therapeutic follow-up.

Myrian®, an advanced radiology visualization solution, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing a new platform

dedicated to oncology, multidisciplinary and collaborative, to optimize patient care and follow-up. A Guerbet Group subsidiary since June 2023, Intrasense continues to enrich its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

More information at www.intrasense.fr

Guerbet

Christine Allard

Head of Public Affairs and Communications
Phone: +33 6 30 11 57 82

christine.allard@guerbet.com

Intrasense

Salomé Sylvestre

Communications officer
Phone: +33 4 67 13 01 30

investisseurs@intrasense.fr

NewCap

Thomas Grojean

Financial Communication and
Investor relations
Phone: +33 1 44 71 20 40

intrasense@newcap.eu